Focal cryoablation for unifocal prostate cancer: report of 12 cases
10.3760/cma.j.issn.1000-6702.2011.09.003
- VernacularTitle:冷冻治疗单病灶前列腺癌12例临床分析
- Author:
Huibo LIAN
;
Wei WANG
;
Rong YANG
;
Feng QU
;
Gutian ZHANG
;
Weidong GAN
;
Xiaogong LI
;
Lingqi ZENG
;
Hongqian GUO
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Cryosurgery
- From:
Chinese Journal of Urology
2011;32(9):588-590
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate term efficacy of focal cryoablation for localized single lesion prostate cancer and the protection of erectile function.MethodsFrom June 2008 to December 2009, 12 patients with localized single lesion prostate cancer were treated with focal cryoablation. All diagnoses were confirmed by transrectal ultrasound-guided prostatic biopsy. The mean Gleason score was ≤ 7; three cases had a Gleason score of 5, five cases a score of 6, and four cases a score of 7. The average preoperative value of PSA was 9.7 ng/ml ( 4.2 - 14.9 ng/ml ). The PSA level was obtained every three months for the first year and then every six months thereafter. Patients with a PSA nadir greater than 1.0 ng/ml or if the PSA nadir increased more than 2 ng/ml underwent repeat biopsy to exclude tumor recurrence.ResultsThe mean operative time was (82 ±26) minutes. The mean postoperative hospital stay was (5 ± 2) days. After catheter removal, all 12 cases had good continence and 10 had erectile function before surgery. Of the 10 patients, eight had erectile function after surgery. The follow - up ranged from 12 to 30 months ( mean 23 ).The lowest average serum PSA nadir was 2.2 ng/ml, nine patients had a minimum PSA nadir of less than 1.0 ng/ml and three had a minimum PSA nadir of more than 1.0 ng/ml. Four patients underwent repeat biopsy after abnormal PSA, and prostate cancer was detected in the contralateral gland in one patient.ConclusionsUltrasound-guided transperineal focal cryoablation is a safe and effective treatment with few complications for localized single lesion prostate cancer. Additional studies with longer follow-up are necessary for long-term efficacy.
